Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercepharma.com
FiercePharma
Get the latest updates from FiercePharma directly as they happen.
Follow now 363 followers
Latest posts
Last updated about 12 hours ago
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
about 12 hours ago
A rival bidder has emerged to acquire struggling gene therapy specialist bluebird...
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
about 17 hours ago
After much delay, Novartis has finally won a key FDA go-ahead for...
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
about 17 hours ago
Over the last three years, the FDA has approved six new drugs...
Pharma Marketing in 2025: A Conversation with Fierce Pharma
about 17 hours ago
Pharma Marketing in 2025: A Conversation with Fierce Pharma
Eli Lilly's Alzheimer's contender Kisunla gets thumbs down from EU regulators over safety concerns
about 20 hours ago
After failing to pass muster with England’s drug reimbursement watchdog earlier this...
Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M
about 21 hours ago
Gilead CEO Daniel O’Day saw another rise in his pay in 2024...
AstraZeneca, Sanofi, Lilly, Pfizer CEOs meet with Xi Jinping amid US-China trade tensions
about 21 hours ago
As U.S. President Donald Trump threatens a new round of tariffs as...
Senate investigation claims Pfizer shifted profits offshore in what could be pharma's 'largest tax-dodging scheme'
about 21 hours ago
Four years into a Congressional probe of Big Pharma’s potential abuse of...
Moderna brand chief Kate Cronin leaves for 'next chapter'
about 21 hours ago
Kate Cronin, who took the marketing reins at Moderna in 2021 as...
Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians
about 22 hours ago
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their...
Fierce Pharma Asia—Novo's triple G obesity bet; Merck's latest China deal; Hengrui, Elevar's 2nd FDA snub
about 23 hours ago
Novo Nordisk snagged an obesity asset from China's United Laboratories for up...
Manufacturing issues trip up Milestone's long-awaited FDA landmark
about 23 hours ago
The FDA has rejected Milestone Pharmaceuticals’ application for approval of Cardamyst (etripamil)...